Intuitive Surgical, Inc.
ISRGIntuitive Surgical is building a razor-and-blade ecosystem in surgery, where every installed robot drives years of high margin recurring revenue.
Because once a hospital commits to a surgical platform, switching is costly, slow, and risky.
Business Model
Devices plus services
Sell a surgical robot upfront, then earn recurring revenue from instruments, accessories, and service contracts.
Economic Engine
High cash generation
Gross margins of 66 percent and net margins of 28.4 percent turn each procedure into durable profit.
Long-Term Lens
Ecosystem durability
The key question is whether da Vinci remains the standard platform in operating rooms worldwide.
BinaPrint Snapshot
Style
Build
Fitness
Strong
Updated Mar 8, 2026
On this page
Company Story
How do Intuitive Surgical, Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A surgical robotics ecosystem with recurring revenue and 28 percent net margins that could compound for decades if it keeps owning the operating room.”
What does Intuitive Surgical, Inc. actually do?
Intuitive Surgical designs and sells robotic systems that help surgeons perform minimally invasive operations.
- Builds the da Vinci surgical robot used in hospitals
- Provides instruments and tools used in each procedure
- Maintains and services the installed robots
Why it matters
It sits inside the operating room
Once a hospital installs a system and trains surgeons on it, it becomes part of core medical infrastructure.
How does Intuitive Surgical, Inc. make money?
It sells robotic systems upfront and then earns recurring revenue every time the robot is used.
- Capital sales of multi million dollar robotic systems
- Recurring sales of instruments and accessories per surgery
- Service contracts that keep systems running
Economic clue
High margins
A 66 percent gross margin and 28.4 percent net margin show pricing power and valuable recurring revenue.
Why do long-term investors keep Intuitive Surgical, Inc. on the radar?
It benefits from aging populations and the global shift toward minimally invasive surgery.
- Revenue has grown about 15 percent per year on average over five years
- Earnings per share have grown about 13.7 percent per year over five years
- Recent year revenue growth reached 20.5 percent
Investor takeaway
A growth platform with scale
Strong double digit growth combined with high margins is rare in medical hardware.
Based on company financial statements.
What Could Change The Story
- Proved it would move the profile toward Venture.
- Matured would move the profile toward Vault.
Benchmark Comparison
How has Intuitive Surgical, Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$2,061
+106.1% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| ISRG | +106.1% | $2,061 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Intuitive Surgical, Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- A long runway from global adoption of robotic surgery
- High margin businesses that reinvest instead of paying dividends
- Exposure to healthcare innovation with strong balance sheet quality
Be Careful If You Expect
- Steady dividends, it pays none
- Short term predictability, hospital budgets can be cyclical
- Flat margins, recent margins are contracting
What To Watch Over Time
- Procedure growth per installed system
- Competitive entries from large medical device companies
- Whether operating margin holds near 29 percent or erodes
BinaPrint Position
Where does Intuitive Surgical, Inc. sit on the BinaPrint map right now?
Test whether business quality and financial profile match the company's stated narrative.
Advanced BinaPrint details
Open the axes, investor fit, and risk framing behind this profile.
Key Metrics
Which metrics matter most for Intuitive Surgical, Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
15.2% 5-year average
13.7% 5-year average
66% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 15.2% 5-year average | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 13.7% 5-year average | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 66% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Intuitive Surgical, Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
13.0% ROIC
66.0% gross margin
24.7% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 13.0% ROIC | The business is currently showing fair capital efficiency. |
| Profitability | 66.0% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 24.7% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Intuitive Surgical, Inc.?
Intuitive Surgical, Inc. currently appears in these ETF and fund proxies.
QQQ
Invesco QQQ Trust, Series 1
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Intuitive Surgical, Inc.?
Company-specific questions readers often ask about Intuitive Surgical, Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
It builds and sells robotic surgical systems that allow doctors to perform minimally invasive operations with greater precision.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
The installed base of robotic systems creates switching costs, as hospitals train surgeons and build workflows around da Vinci, making replacement risky and expensive.
Aging populations worldwide increase surgical volumes, and minimally invasive procedures continue to gain share over open surgery.
High gross margins of 66 percent provide room to invest heavily in research and defend its lead against competitors.
Revenue has grown about 15 percent per year over five years, showing durable adoption rather than one cycle of equipment sales.
Bear case
What can break
Large diversified medical device companies could invest aggressively in competing robotic platforms and compress pricing over time.
If hospitals face reimbursement cuts or tighter budgets, capital purchases of expensive robotic systems could slow materially.
A breakthrough non surgical treatment or less invasive technology could reduce the need for certain robotic procedures.
If margin contraction continues from 29.3 percent operating margin to materially lower levels, the premium economics could erode.
Risk Radar
Key Risks
Where downside pressure can build.
Competitive risk, new robotic systems from major device makers could pressure a 29.3 percent operating margin.
Hospital spending cycles, large capital systems represent significant upfront costs that may be delayed in downturns.
Procedure concentration, heavy reliance on robotic assisted surgery volumes for recurring instrument revenue.
Pressure points
Concentration risk
A significant portion of revenue is tied to the da Vinci platform and the procedures performed on it. If a superior competing platform gained share, both system sales and recurring instrument revenue could be affected at once.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $490.16
- Daily move
- -1.32%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.